Literature DB >> 33756041

Novel SPTBN2 gene mutation and first intragenic deletion in early onset spinocerebellar ataxia type 5.

Romina Romaniello1, Andrea Citterio2, Elena Panzeri2, Filippo Arrigoni3, Marta De Rinaldis4, Antonio Trabacca4, Maria Teresa Bassi2.   

Abstract

In the present study, we describe two novel cases of SCA5 with early onset. The first one, carrying a novel heterozygous de novo missense mutation in SPTBN2 gene, showed a striking very severe cerebellar atrophy and reduction of volume of the pons at a very young age (16 months). The latter, carrying the first de novo intragenic deletion so far reported in SPTBN2 gene, showed a mild cerebellar atrophy involving the hemispheres and a later onset. In both cases, for the first time, a hyperintense signal of the dentate nuclei was observed.
© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33756041      PMCID: PMC8045899          DOI: 10.1002/acn3.51345

Source DB:  PubMed          Journal:  Ann Clin Transl Neurol        ISSN: 2328-9503            Impact factor:   4.511


Introduction

Inherited ataxias are a clinically rare and genetically heterogeneous group of disorders characterized by progressive cerebellar ataxia, incoordination, dysarthria, and difficulty in swallowing, due to pathogenic variants in more than 100 genes identified so far. , , Two major groups of ataxia are described: autosomal dominant cerebellar ataxias (also known as spinocerebellar ataxia, SCA) leading to an adult‐onset ataxia and autosomal recessive cerebellar ataxias (also known as SCARs). In recent years, it has become clear that the monoallelic or biallelic state of the pathogenic variant is responsible for adult‐ or infantile‐onset cerebellar ataxia. Among these, SCA type 5 (SCA5) is a dominant ataxia associated with spectrin beta non‐erythrocytic 2 (SPTBN2) gene mutations, characterized by a slowly progressive ataxia with typical adult‐onset and global cerebellar atrophy at brain magnetic resonance image (MRI). , , , , The SPTBN2 gene (11q13.2) encodes the b‐III spectrin protein, which is primarily expressed in the Purkinje cells of the cerebellum, and it is involved in trafficking and anchoring of crucial neurotransmitter transporters and ion channels to neuronal cell membranes. , , , , , Recently, 11 cases of infantile‐onset SCA5 have been reported, all showing global developmental delay, eye movement anomalies, and cerebellar ataxia, carrying either missense or truncating heterozygous mutations in SPTBN2 gene. , , , , , , , In the present study, we describe two new cases of SCA5 with early onset. The first one, carrying a novel heterozygous de novo missense mutation in SPTBN2 gene, shows a very severe cerebellar atrophy at onset. The latter carries the first de novo intragenic deletion so far reported in SPTBN2 gene.

Methods

The patients’ parents provided written informed consent to the research and to the publication of the results. Study approval by the Ethics committee was provided by the E. Medea Scientific Institute Ethic Committee. The probands' DNA were screened using a targeted next‐generation sequencing (NGS) approach with a panel of 231 genes. The deletion was identified using ExomeDepth, a powerful bioinformatic tool realized to identify CNVs in exome samples and in NGS data from gene panels. Further details are provided in File S1. Patients underwent cerebral MRI at 1.5 and 3T. In both cases, multiplanar T1‐ and T2‐weighted images were acquired with age‐appropriate TR and TE values. Sedation was required to perform the MRI.

Results

The clinical, genetic, and neuroradiological features of the two patients herein described and the 11 patients described up to date with early onset SCA5 are summarized in Table 1. For a detailed description of the two novel patients, see File S1.
Table 1

Features of the two patients herein described and patients described up to date with early onset SCA5

PatientSex SPTBN2 gene mutationInheritanceClinical onsetDevelopmental delayPyramidal signsCerebellar findingsDystonia/DyskinesiaOcular findingsBrain MRI
This Study
ID 91618M

c.185C > A

p. Thr62Asn

het

de novo5 mo+Brisk reflexesHypotonia, ataxiaNystagmus, strabismus16 mo: severe CA involving both the hemispheres and vermis, with abnormal hyperintense signal of the dentate nuclei. The pons was reduced in volume
ID 14020F

c.1653 + 697_4278+353; p.(Lys551_Gln1426del)

g.66463395_66474289del10895

het

de novo10 mo+Brisk reflexesAtaxia, tremorStrabismus3 yrs: mild CA involving the hemispheres associated with hyperintense signal of the dentate nuclei. The brainstem and supratentorial brain were normal
Other studies
JacobF

c.1438C > T

p. Arg480Trp

het

na 12 mo+Brisk reflexesAtaxia, tremorNystagmus

1 yrs: diffuse cerebellar hypoplasia

2 yrs and 9 yrs: mild progression of the CA

Parolin‐SchnekenbergF

c.1438C > T

p. Arg480Trp

het

de novo8 mo+AtaxiaStrabismusMild CA
MizunoF

c.1309C > G

p. Arg437Gly

het

de novo10 mo+Ataxia, tremor, dysarthriaNystagmus10 mo and 2 yrs: moderate CA and mild pontine atrophy
NuovoF

c.1438C > T

p. Arg480Trp

het

de novo12 mo+Ataxia, dysarthriaNystagmus1 yrs10/12 : global cerebellar hypoplasia
NicitaM

c.479C > T

p. Phe160Cys

het

de novo5 mo+AtaxiaStrabismusProgressive CA
F

c.185C > T

p. Thr62Ile

het

na 8 mo+AtaxiaNystagmusCA
F

c.1309C > T

p. Arg437Trp

het

de novo10 mo+AtaxiaCA
M

c.1310C > A

p. Arg437Gln

het

de novo5 mo+Brisk reflexesAtaxia, tremorNystagmusProgressive CA
AccogliF

c.1310G > A

p. Arg437Gln

het

de novo2 yrs+Brisk reflexesAtaxia, dysarthriaNystagmus

13 mo: CA (vermis > hemispheres)

4 yrs: progressive CA

ReaM

c.812C > T

p. Thr271Ile

het

de novo6 mo+Brisk reflexesAtaxiaDystonia

1 yr: normal

7 yrs: mild hemisphere CA

8 yrs: hemisphere and vermis CA

ZontaF

c.1438C > T

p. Arg480Trp

het

de novo17 mo++Hypotonia, ataxia, intentional tremorStrabismus2 yrs: cerebellar and vermian hypoplasia with enlargement of cerebrospinal fluid spaces and IV ventricle

+, present; −, absent; CA, cerebellar atrophy; F, female; M, male; mo, months; MRI, magnetic resonance imaging; na, not available; yrs, years.

Features of the two patients herein described and patients described up to date with early onset SCA5 c.185C > A p. Thr62Asn het c.1653 + 697_4278+353; p.(Lys551_Gln1426del) g.66463395_66474289del10895 het c.1438C > T p. Arg480Trp het 1 yrs: diffuse cerebellar hypoplasia 2 yrs and 9 yrs: mild progression of the CA c.1438C > T p. Arg480Trp het c.1309C > G p. Arg437Gly het c.1438C > T p. Arg480Trp het c.479C > T p. Phe160Cys het c.185C > T p. Thr62Ile het c.1309C > T p. Arg437Trp het c.1310C > A p. Arg437Gln het c.1310G > A p. Arg437Gln het 13 mo: CA (vermis > hemispheres) 4 yrs: progressive CA c.812C > T p. Thr271Ile het 1 yr: normal 7 yrs: mild hemisphere CA 8 yrs: hemisphere and vermis CA c.1438C > T p. Arg480Trp het +, present; −, absent; CA, cerebellar atrophy; F, female; M, male; mo, months; MRI, magnetic resonance imaging; na, not available; yrs, years.

Patient ID 91618

The patient was the only child (male) of non‐consanguineous healthy parents. Perinatal history was normal. Since the first year of life, main developmental milestones appeared delayed and an impairment in social and communication skills was evident. At the age of 16 months, neurological examination showed poor social and communicative interaction, absence of expressive language, axial hypotonia, ataxia, increased deep tendon reflexes, clumsiness, and crawling. Brain MRI at 16 months of age documented a severe cerebellar atrophy involving both the hemispheres and vermis, with abnormal hyperintense signal of the dentate nuclei (Fig. 1A). The pons showed reduced volume. NGS of a panel of 231 genes (see File S1) showed a novel heterozygous variant c.185C > A (p. Thr62Asn) in SPTBN2 gene. The variant was not present in any of the parents suggesting a de novo origin. The variant was not present in any public database. Predictions of possible pathogenicity were obtained with different software as detailed in File S1. The Thr62 residue is already known to be involved in a mutation, p. Thr62Ile (c.185C > T) . The amino acid change falls within the calponin homology domain of b‐III spectrin protein (Fig. 2A and B).
Figure 1

MRI findings. Patient 1 (row A) at 16 months of age shows a severe vermian and cerebellar atrophy with associated relative pontine atrophy. Patient 2 (row B) at 3 years of age has a milder degree of cerebellar atrophy with a normal pons. In both subjects, dentate nuclei have a hyperintense abnormal signal on T2‐weighted sequences (arrowheads).

Figure 2

Patient’s pedigrees and mutations. Panel (A) represents the patients 91,618 and 14,020 pedigrees. Electropherograms of the mutant and wild‐type sequence in patient and in the parents, respectively, are shown. On the right, gel electrophoresis of genomic amplification product in patient 14,020 and control using primer encompassing the putative deleted region. A fragment of approximately 2000 bp is amplified in patient’s DNA only containing the deletion breakpoint. Panel (B) shows a schematic representation of the SPTBN2 protein with the known functional domains, the known mutations (italics character), and the mutations identified in the patients herein described (boxed). The dashed line indicates the deleted region. Acc. N. of the SPTBN2 genomic and protein sequences are NM_006946.2 and NP_008877.1, respectively.

MRI findings. Patient 1 (row A) at 16 months of age shows a severe vermian and cerebellar atrophy with associated relative pontine atrophy. Patient 2 (row B) at 3 years of age has a milder degree of cerebellar atrophy with a normal pons. In both subjects, dentate nuclei have a hyperintense abnormal signal on T2‐weighted sequences (arrowheads). Patient’s pedigrees and mutations. Panel (A) represents the patients 91,618 and 14,020 pedigrees. Electropherograms of the mutant and wild‐type sequence in patient and in the parents, respectively, are shown. On the right, gel electrophoresis of genomic amplification product in patient 14,020 and control using primer encompassing the putative deleted region. A fragment of approximately 2000 bp is amplified in patient’s DNA only containing the deletion breakpoint. Panel (B) shows a schematic representation of the SPTBN2 protein with the known functional domains, the known mutations (italics character), and the mutations identified in the patients herein described (boxed). The dashed line indicates the deleted region. Acc. N. of the SPTBN2 genomic and protein sequences are NM_006946.2 and NP_008877.1, respectively.

Patient ID 14020

The patient was the only child (female) of distant consanguineous healthy parents (third‐degree cousins). Main developmental milestones appeared delayed. At the age of 20 and 29 months, simple febrile seizures occurred (2–3 min). Repeated EEGs showed during sleep poor organization of background activity without epileptic abnormalities. Brain MRI at 3 years of age showed only mild cerebellar atrophy involving the hemispheres associated with hyperintense signal of the dentate nuclei (Fig. 1B). The brainstem and supratentorial brain were normal. At the age of 37 months, neurological examination showed microcephaly (head circumference 40.9 cm, <3rd centile), poor verbal language (few words), diffuse hypotonia, increased deep tendon reflexes, presence of bilateral Babinski sign, mild dysmetria and tremor, and gait ataxia. A mild developmental delay was documented. Targeted NGS did not lead to any pathogenic variant, but the analysis with ExomeDepth detected a putative heterozygous deletion in SPTBN2 spanning from exon 13 to 20, confirmed by quantitative PCR (qPCR) (data not shown). We subcloned and sequenced the junction fragment from patient genomic DNA (Fig. 2A and B) and we identified two AluSx elements flanking the two breakpoints in intron 12 and 20, which represent the microhomology domains mediating a deletion of 10895bp (g.66463395_66474289del10895) as shown in Figure 3A and B. The deletion was not present in any of the parents suggesting a de novo origin in the patient. Several attempts were made to confirm the deletion at cDNA level starting from RNA extracted from patient’s blood. Due to the lack of SPTBN2 gene expression in blood, no amplification products were obtained. Patient’s parents refused skin biopsy, therefore we can only suppose that the genomic deletion generates an in‐frame cDNA deletion from exons 13 to 20, producing a putative protein lacking 875 amino acid residues (p.(551Lys_Gln1426del)) within the spectrin repeats of the SPTBN2 protein (Fig. 3C).
Figure 3

Characterization of the deletion breakpoint in Pt 14020. Panel (A) indicates the patient’s genomic DNA sequence encompassing the breakpoint. Panel (B) shows the patient’s genomic DNA sequence alignment between the two intronic regions flanking the breakpoint and containing the AluSx repeats. Panel (C) is a schematic representation of the genomic SPTBN2 deletion of 10895 bp, which generates a putative in‐frame cDNA deletion encompassing exons 13 to 20 of SPTBN2 gene thereby leading to a putative protein missing 875 aa residues.

Characterization of the deletion breakpoint in Pt 14020. Panel (A) indicates the patient’s genomic DNA sequence encompassing the breakpoint. Panel (B) shows the patient’s genomic DNA sequence alignment between the two intronic regions flanking the breakpoint and containing the AluSx repeats. Panel (C) is a schematic representation of the genomic SPTBN2 deletion of 10895 bp, which generates a putative in‐frame cDNA deletion encompassing exons 13 to 20 of SPTBN2 gene thereby leading to a putative protein missing 875 aa residues.

Discussion

In recent years, an increasing number of infantile‐onset autosomal recessive cerebellar ataxias associated with heterozygous SPTBN2 gene mutations (SCA5) were described. The SPTBN2 protein, expressed in soma and dendrites of cerebellar Purkinje cells, is required for the maintenance of dendritic architecture and for the trafficking and stabilization of several membrane proteins. Mutations in SPTBN2 gene alter dendritic morphology and density and cause changes in Purkinje cells’ intrinsic excitability. This reduces sodium currents and causes deficits in glutamatergic neurotransmission. To date, 11 infantile‐onset cases of dominant SPTBN2 gene mutations have been reported, four with the same p. Arg480Trp mutation, all showing the common phenotype of developmental delay in early infancy, evolving into intellectual disability and ataxia. Hyperreflexia, dystonia, and eye movement anomalies can be variously present. Herein we describe two novel SCA5 cases with early onset. Clinical findings of both our cases are completely in line with literature. Nevertheless, at brain MRI, the first one showed a striking, very severe cerebellar atrophy at a very young age (16 months) with a global volume reduction of hemispheres and vermis associated with a marked deepening and enlargement of folia sulci and cortical subarachnoid spaces, pons hypoplasia, and a normal‐appearing supratentorial brain. The second one showed only a mild cerebellar atrophy. These findings are quite in line with literature reports in which a cerebellar vermis and hemispheric hypoplasia or atrophy of varying degrees with no evidence of cortical involvement are described. , , , , , , , Further, this is the report of the second case of brainstem involvement (pons hypoplasia) so far documented. In addition, in both our cases, a hyperintense signal of the dentate nuclei was observed, a finding not described in literature up to now associated with SCA5, but found in association with cerebrotendinous xanthomatosis and methotrexate toxicity, both conditions clinically excluded in our patients. From a genetic point of view, the first patient herein reported carried a novel heterozygous de novo missense mutation in SPTBN2 gene, while the second one harbored the first intragenic deletion of 10895 bp that spans from intron 12 to 20 of the SPTBN2 gene and leads to a putative protein lacking 875 amino acid within the spectrin repeat region. AluSx sequences were found to flank the breakpoint and likely mediate the deletion event. It is well known that homologous recombination between dispersed Alu sequences can lead to genetic changes, such as duplications, deletions, and translocations, in different disease genes. These sequences of about 300 base pairs share a great level of identity and allow more efficient homologous recombination than sequences with an imperfect identity which would represent an inefficient target. , The suggested minimum requirement for favorable homologous recombination is 75% of identity between Alu elements. , In our study, we hypothesize that the de novo deletion of 10895 bp in SPTBN2 gene was generated by an unequal homologous recombination event, due to a misalignment between Alu Sx in intron 12 (5ʹ deletion boundary) of SPTBN2 gene and Alu Sx in intron 20 (3ʹ deletion boundary). Both Alu Sx show 86% sequence identity (91% without gaps) and a microhomology domain of 50 bp. This homology is comparable to that previously reported by Rossetti et al in the factor VIII coagulation gene and that reported by Zhang et al in the mitochondrial acetoacetyl‐CoA thiolase (T2) gene. , These studies let us speculate that, also in our case, unequal homologous recombination between Alus was the likely mechanism for this deletion, adding the dominant SCA due to SPTBN2 mutations to the group of the genetic disorders having Alu/Alu recombination as underlying genetic mechanism. Of note, the second patient, carrying the intragenic deletion of SPTBN2 gene, showed a milder clinical (later onset) and neuroradiological phenotype than the patient with the missense mutation. In conclusion, the authors present two novel cases of infantile‐onset SCA associated with a novel SPTBN2 mutation—the first with an early severe cerebellar involvement and the latter with the first intragenic deletion so far reported.

Conflict of Interest

The authors declare no conflict of interest.

Author Contributions

Romaniello performed acquisition of data and funding; drafted the manuscript. Arrigoni performed neuroradiological study and was involved in revising critically the manuscript. Citterio performed molecular data. De Rinaldis performed acquisition of data. Trabacca performed acquisition of data. Panzeri performed molecular data and was involved in revising critically the manuscript. Bassi was involved in revising critically the manuscript and in acquisition of funding. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. File S1. Material and Methods and the two Patients herein described. Click here for additional data file.
  23 in total

1.  Between SCA5 and SCAR14: delineation of the SPTBN2 p.R480W-associated phenotype.

Authors:  Sara Nuovo; Alessia Micalizzi; Stefano D'Arrigo; Monia Ginevrino; Tommaso Biagini; Tommaso Mazza; Enza Maria Valente
Journal:  Eur J Hum Genet       Date:  2018-05-25       Impact factor: 4.246

2.  A Japanese SCA5 family with a novel three-nucleotide in-frame deletion mutation in the SPTBN2 gene: a clinical and genetic study.

Authors:  Ying Wang; Kishin Koh; Michiaki Miwa; Nobuo Yamashiro; Kazumasa Shindo; Yoshihisa Takiyama
Journal:  J Hum Genet       Date:  2014-08-21       Impact factor: 3.172

3.  Identification of Alu-mediated, large deletion-spanning exons 2-4 in a patient with mitochondrial acetoacetyl-CoA thiolase deficiency.

Authors:  Gaixiu Zhang; Toshiyuki Fukao; Satomi Sakurai; Keitaro Yamada; K Michael Gibson; Naomi Kondo
Journal:  Mol Genet Metab       Date:  2006-08-28       Impact factor: 4.797

4.  Spectrin mutations cause spinocerebellar ataxia type 5.

Authors:  Yoshio Ikeda; Katherine A Dick; Marcy R Weatherspoon; Dan Gincel; Karen R Armbrust; Joline C Dalton; Giovanni Stevanin; Alexandra Dürr; Christine Zühlke; Katrin Bürk; H Brent Clark; Alexis Brice; Jeffrey D Rothstein; Lawrence J Schut; John W Day; Laura P W Ranum
Journal:  Nat Genet       Date:  2006-01-22       Impact factor: 38.330

5.  A family with spinocerebellar ataxia type 5 found to have a novel missense mutation within a SPTBN2 spectrin repeat.

Authors:  Ellen Cho; Brent L Fogel
Journal:  Cerebellum       Date:  2013-04       Impact factor: 3.847

6.  Spectrin mutations that cause spinocerebellar ataxia type 5 impair axonal transport and induce neurodegeneration in Drosophila.

Authors:  Damaris N Lorenzo; Min-gang Li; Sarah E Mische; Karen R Armbrust; Laura P W Ranum; Thomas S Hays
Journal:  J Cell Biol       Date:  2010-04-05       Impact factor: 10.539

7.  Homeologous recombination between AluSx-sequences as a cause of hemophilia.

Authors:  Liliana C Rossetti; Anne Goodeve; Irene B Larripa; Carlos D De Brasi
Journal:  Hum Mutat       Date:  2004-11       Impact factor: 4.878

Review 8.  Spinocerebellar ataxia type 5: clinical and molecular genetic features of a German kindred.

Authors:  K Bürk; C Zühlke; I R König; A Ziegler; E Schwinger; C Globas; J Dichgans; Y Hellenbroich
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

Review 9.  A Novel Homozygous Mutation in SPTBN2 Leads to Spinocerebellar Ataxia in a Consanguineous Family: Report of a New Infantile-Onset Case and Brief Review of the Literature.

Authors:  Mohammad A Al-Muhaizea; Faten AlMutairi; Rawan Almass; Safinaz AlHarthi; Mazhor S Aldosary; Maysoon Alsagob; Ali AlOdaib; Dilek Colak; Namik Kaya
Journal:  Cerebellum       Date:  2018-06       Impact factor: 3.847

10.  Infantile Onset of Spinocerebellar Ataxia Type 5 (SCA-5) in a 6 Month Old with Ataxic Cerebral Palsy.

Authors:  Gillian Rea; Sandya Tirupathi; Jonathan Williams; Penny Clouston; Patrick J Morrison
Journal:  Cerebellum       Date:  2020-02       Impact factor: 3.847

View more
  2 in total

1.  SPTBN2, a New Biomarker of Lung Adenocarcinoma.

Authors:  Chunli Wu; Bo Dong; Lan Huang; Yafei Liu; Guanchao Ye; Shihao Li; Yu Qi
Journal:  Front Oncol       Date:  2021-10-20       Impact factor: 6.244

2.  SPTBN2 Promotes the Progression of Thyroid Cancer by Accelerating G1/S Transition and Inhibiting Apoptosis.

Authors:  Xiaofen Zhou; Lizhi Lin; Yufeng Qi; Min Xu; Qiding Xu; Yinghao Wang; Jinmiao Qu
Journal:  Dis Markers       Date:  2022-08-03       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.